Lindsay Davies – VJRegenMed

MSCs for type I diabetes

admin_vjr_user — Mon, 23 Aug 2021 17:29:15 +0000

Lindsay Davies, PhD, Karolinska Institutet & NextCell Pharma AB, Huddinge, Sweden, describes the rationale behind mesenchymal stromal cell (MSC)-based therapy for Type I diabetes (T1D). Dr Davies describes a strategy that involves the administration of a single dose of MSCs, with the aim of re-educating of the patient’s immune system and restoring beta cell function, thus reducing the co-morbidities associated with late-stage T1D, such as chronic wounds. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

The benefits of Wharton’s jelly-derived MSCs

admin_vjr_user — Mon, 23 Aug 2021 17:29:14 +0000

Lindsay Davies, PhD, Karolinska Institutet & NextCell Pharma AB, Huddinge, Sweden, describes the benefits associated with the use of Wharton’s jelly-derived mesenchymal stromal cells (WJ-MSCs) compared to other MSC sources. WJ-MSCs are easily accessible from umbilical cord tissue, are highly immunomodulatory, can be used to generate large doses of cell product and are associated with fewer ethical issues compared to bone marrow-derived MSCs, given their ease of access and non-invasive methods of procurement. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

ProTrans: Wharton’s jelly-derived MSC therapy for type I diabetes

admin_vjr_user — Mon, 23 Aug 2021 17:29:12 +0000

Lindsay Davies, PhD, Karolinska Institutet & NextCell Pharma AB, Huddinge, Sweden, describes a single center Phase II trial (NCT03406585) evaluating ProTrans, an allogeneic Wharton’s jelly-derived mesenchymal stromal cell (WJ-MSC)-based product, for the treatment of type I diabetes (T1D). This study demonstrated that a single infusion of ProTrans in adult patients with T1D resulted in maintenance of beta cell function, measured through the delta-change of C-peptide Area Under the Curve (AUC). There are currently plans to evaluate this therapy in a multicenter Phase III trial, as well as in a pediatric patient population. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.